source
- Vaderis raises $152 million to launch late-stage trials of AKT inhibitor engasertib for rare bleeding disorderVaderis Therapeutics announced a $152 million Series B financing round, giving it sufficient capital to advance its experimental AKT-targeting drug, engasertib. The company has also begun late-sta…
- FDA rejects ITM radiopharma therapy while WHO defends immunization schedulesThe U.S. Food and Drug Administration has issued a rejection of a radiopharmaceutical therapy identified as ITM, indicating that the product did not meet the agency's requirements for approval. Th…